8-KEarnings & ResultsAcquisitions & DispositionsExhibits & Filings

ELI LILLY & Co 8-K Report, Acquisition Completed (Jan 31, 2007)

Filed January 31, 2007For Securities:LLY

Summary

Eli Lilly & Company (LLY) filed an 8-K on January 31, 2007, announcing the completion of its acquisition of ICOS Corporation for approximately $2.3 billion, or $34 per share. This strategic move significantly expands Lilly's portfolio, particularly in key therapeutic areas. The filing also includes a press release detailing Lilly's fourth quarter and full-year 2006 financial results. Notably, the company provided financial expectations for 2007, offering both GAAP and adjusted earnings per share guidance. Lilly emphasizes its use of non-GAAP financial measures to provide a clearer view of ongoing operational performance, excluding charges related to product liability, asset impairments, restructuring, and accounting changes. Investors should carefully consider these adjusted figures alongside GAAP results to understand the company's underlying business trends and future outlook.

Key Highlights

  • 1Completed acquisition of ICOS Corporation for approximately $2.3 billion ($34/share) on January 29, 2007.
  • 2The acquisition is expected to enhance Lilly's product portfolio and market presence.
  • 3Announced fourth quarter and full-year 2006 financial results.
  • 4Provided full-year 2007 financial expectations, including both GAAP and adjusted EPS guidance.
  • 5Utilizes non-GAAP financial measures (adjusted net income, adjusted EPS) for enhanced operational clarity.
  • 6Adjusted results exclude significant charges such as product liability, asset impairment, restructuring, and accounting changes from prior periods.
  • 7Management uses non-GAAP measures internally for performance evaluation and resource allocation.

Frequently Asked Questions

The primary purposes of this 8-K filing were to announce the completion of Eli Lilly's acquisition of ICOS Corporation and to provide the company's fourth quarter and full-year 2006 financial results, along with 2007 financial expectations.

Eli Lilly acquired ICOS Corporation for approximately $2.3 billion, at a price of $34 per share for all outstanding common stock.

Eli Lilly uses non-GAAP financial measures, such as adjusted net income and adjusted diluted earnings per share, to provide investors with a more meaningful comparison of ongoing operational performance. These measures exclude items that are typically highly variable, difficult to predict, and can significantly impact reported results, such as charges for product liability, asset impairments, restructuring, and accounting changes.

Lilly adjusts for charges such as product liability matters, asset impairment, restructuring and other special charges, and the cumulative effect of accounting changes like FIN 47. For 2007 guidance, they also adjusted for estimated charges related to manufacturing decisions and in-process R&D from the ICOS acquisition.